Celonic, Carbogen Amcis Partner to Offer Integrated ADC Development & Manufacturing

Celonic Group, a “pureplay” Biologics CDMO, and the Carbogen Amcis Group, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, have joined forces to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution.

The alliance combines Celonic’s advanced biologics capabilities with CARBOGEN AMCIS’s expertise in payload synthesis, conjugation, and sterile fill-finish, creating a seamless, end-to-end platform for ADC innovators.

This partnership addresses a critical need in the biopharmaceutical sector, where the complexity of ADC development often necessitates collaboration between multiple vendors. By combining their strengths, Celonic and CARBOGEN AMCIS aim to streamline the supply chain, speed up timelines, and support clients from early-stage development through to commercial launch.

“This strategic alliance is a direct response to the evolving needs of ADC innovators,” said Dr. Samanta Cimitan, CEO of Celonic Group. “By integrating Celonic’s advanced biologics platforms with CARBOGEN AMCIS’s world-class payload and conjugation capabilities, we’re enabling a fully harmonized development and manufacturing pathway, from DNA to drug product. It’s a scalable, compliant, and commercially ready solution designed to accelerate innovation and reduce complexity for our partners.”

“The new targeted cancer treatments have fueled a rising demand for ADCs, and this alliance positions us to meet that demand with unmatched technical expertise and operational agility,” said Stephan Fritschi, CEO of Carbogen Amcis Group. “Together, we offer a comprehensive service for ADC development, streamlined, scalable, and globally compliant.”

The integrated offering includes:

• Cell line development and antibody production at scale (Celonic)
• Payload and linker synthesis and at scale manufacturing (CARBOGEN AMCIS)
• ADC conjugation and sterile fill-finish (CARBOGEN AMCIS)
• Regulatory support and CMC documentation for IND, IMPD, and BLA filings

With Celonic upstream and CARBOGEN AMCIS downstream, teams get one accountable partner. This alliance removes variability and removes handoffs so that such life-saving therapies reach patients sooner.